{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:32Z","timestamp":1786982192302,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04518-y","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:55:30Z","timestamp":1767027330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E\u2013Mutant papillary thyroid carcinoma"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7145","authenticated-orcid":false,"given":"Fernando","family":"Jerkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahiara","family":"Woniatczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-3294","authenticated-orcid":false,"given":"Erika","family":"Abelleira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"4518_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"B.R. Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26, 1\u2013133 (2016) https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"4518_CR2","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C. De Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, De F. Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006) https:\/\/doi.org\/10.1210\/jc.2005-2838","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4518_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M. Schlumberger","year":"2014","unstructured":"3. Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., Pacini, F.: Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2, 356\u2013358 (2014). https:\/\/doi.org\/10.1016\/S2213-8587(13)70215-8","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4518_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G. Riesco-Eizaguirre","year":"2006","unstructured":"G. Riesco-Eizaguirre, P. Guti\u00e9rrez-Mart\u00ednez, M.A. Garc\u00eda-Cabezas, M. Nistal, P. Santisteban, The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane. Endocr. Relat. Cancer. 13, 257\u2013269 (2006) https:\/\/doi.org\/10.1677\/erc.1.01119","journal-title":"Endocr. Relat. Cancer"},{"key":"4518_CR5","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1172\/JCI46382","volume":"121","author":"D. Chakravarty","year":"2011","unstructured":"D. Chakravarty, E. Santos, M. Ryder, J.A. Knauf, X.H. Liao, B.L. West, G. Bollag, R. Kolesnick, T.H. Thin, N. Rosen, P. Zanzonico, S.M. Larson, S. Refetoff, R. Ghossein, J.A. Fagin, Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700\u20134711 (2011) https:\/\/doi.org\/10.1172\/JCI46382","journal-title":"J. Clin. Invest."},{"issue":"10","key":"4518_CR6","first-page":"567","volume":"18","author":"D. Liu","year":"2022","unstructured":"D. Liu et al., Targeted therapy with kinase inhibitors for advanced thyroid cancer. Nat. Rev. Endocrinol. 18(10), 567\u2013584 (2022)","journal-title":"Nat. Rev. Endocrinol."},{"key":"4518_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"A.L. Ho","year":"2013","unstructured":"A.L. Ho, R.K. Grewal, R. Leboeuf, E.J. Sherman, D.G. Pfister, D. Deandreis, K.S. Pentlow, P.B. Zanzonico, S. Haque, S. Gavane, R.A. Ghossein, J.C. Ricarte-Filho, J.M. Dom\u00ednguez, R. Shen, R.M. Tuttle, S.M. Larson, J.A. Fagin, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl. J. Med. 368, 623\u2013632 (2013) https:\/\/doi.org\/10.1056\/NEJMoa1209288","journal-title":"N Engl. J. Med."},{"key":"4518_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","volume":"21","author":"S.M. Rothenberg","year":"2015","unstructured":"S.M. Rothenberg, D.G. McFadden, E.L. Palmer, G.H. Daniels, L.J. Wirth, Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin. Cancer Res. 21, 1028\u20131035 (2015) https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2915","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"4518_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"L.A. Dunn","year":"2019","unstructured":"L.A. Dunn, E.J. Sherman, S.S. Baxi et al., Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J. Clin. Endocrinol. Metab. 104(5), 1417\u20131428 (2019) https:\/\/doi.org\/10.1210\/jc.2018-01478","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4518_CR10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S. Leboulleux","year":"2023","unstructured":"S. Leboulleux, D. Cao, C. Zerdoud, S. Attard, M. Bournaud, C. Lacroix, L. Benisvy, D. Ta\u00efeb, D. Bardet, S. Terroir-Cassou-Mounat, M. Anizan, N. Bouvier-Morel, E. Lamartina, L. Lion, G. Betrian, S. Sajous, C. Schiazza, A. Garcia, M.E. Ciappuccini, R. Schlumberger, M. Borget, A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clin. Cancer Res. 29, 2401\u20132409 (2023) https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046","journal-title":"Clin. Cancer Res."},{"key":"4518_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/thy.2022.0707","volume":"33","author":"J. Wadsley","year":"2023","unstructured":"J. Wadsley, G. Ainsworth, A.B. Coulson, K. Garcez, L. Moss, K. Newbold, K. Farnell, J. Swain, H. Howard, M. Beasley, A. Weaver, K. Wood, J. Marshall, M. Griffin, A. Pascoe, Y. Du, J. Taprogge, G. Flux, S. Brown, Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy. Thyroid. 33, 1119\u20131123 (2023) https:\/\/doi.org\/10.1089\/thy.2022.0707","journal-title":"Thyroid"},{"key":"4518_CR12","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"M. Weber","year":"2022","unstructured":"M. Weber, D. Kersting, B. Riemann, T. Brandenburg, D. F\u00fchrer-Sakel, F. Gr\u00fcnwald, M.C. Kreissl, H. Dralle, F. Weber, K.W. Schmid, K. Herrmann, W. Jentzen, H. Grafe, C. Rischpler, S. Theurer, A. Bockisch, J. Nagarajah, W.P. Fendler, Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Clin. Cancer Res. 28, 4194\u20134202 (2022) https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0437","journal-title":"Clin. Cancer Res."},{"key":"4518_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/thy.2023.0240","volume":"33","author":"S. Leboulleux","year":"2023","unstructured":"S. Leboulleux, D. Benisvy, D. Taieb, M. Attard, C. Bournaud, M. Terroir-Cassou-Mounat, L. Lacroix, N. Anizan, A. Schiazza, M.E. Garcia, A.A. Ghuzlan, L. Lamartina, M. Schlumberger, Y. Godbert, I. Borget, MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid. 33, 1124\u20131129 (2023) https:\/\/doi.org\/10.1089\/thy.2023.0240","journal-title":"Thyroid"},{"key":"4518_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","volume":"13","author":"S. Leboulleux","year":"2025","unstructured":"S. Leboulleux, L. Boucai, N. Busaidy, C. Durante, J.A. Fagin, S. Fazeli, A.G. Gianoukakis, B.R. Haugen, H. Kang, B. Konda, T.W. Laetsch, L. Locati, M. Ryder, C. Spitzweg, F.P. Worden, L. Wirth, A. Ho, Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 13, 516\u2013527 (2025)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4518_CR15","unstructured":"ClinicalTrials.gov. Lenvatinib and Radioiodine (131I) in Combination With a Redifferentiation Strategy in Radioiodine Refractory Thyroid Cancer (NCT04858867). Sponsored by Gustave Roussy. Accessed October 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04858867"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04518-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:55:31Z","timestamp":1767027331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04518-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4518"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04518-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"17"}}